Skip to main content

Table 2 Change in Postpartum Calculated CrCl from Delivery by Postpartum TDF Exposure*

From: Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

Postpartum TDF exposure Change in Calculated CrCl (mL/min) TDF-ART
(N = 445)
ZDV-ART
(N = 447)
ZDV alone
(N = 446)
Week 6—delivery     
 TDF N 188 207 190
  Mean (95% CI) − 23.7 (− 29.6, − 17.8) − 38.6 (− 43.1, − 34.1) − 38.6 (− 42.6, − 34.5)
  Mean difference (95% CI) from TDF-ART   14.9 (7.0, 22.8) 14.8 (6.7, 23.0)
 No TDF N 199 189 212
  Mean (95% CI) − 12.5 (− 20.1, − 5.0) − 27.0 (− 31.0, − 23.0) − 31.7 (− 36.4, − 27.0)
  Mean difference (95% CI) from TDF-ART   14.5 (6.5, 22.5) 19.2 (11.3, 27.0)
Week 26—delivery     
 TDF N 192 206 195
  Mean (95% CI) − 17.9 (− 24.8, − 11.1) − 28.4 (− 34.5, − 22.4) − 29.3 (− 33.3, − 25.3)
  Mean difference (95% CI) from TDF-ART   10.5 (2.1, 18.9) 11.4 (4.0, 18.7)
 No TDF N 193 184 188
  Mean (95% CI) − 8.6 (− 12.8, − 4.3) − 19.0 (− 25.7, − 12.3) − 26.2 (− 31.6, − 20.9)
  Mean difference (95% CI) from TDF-ART   10.4 (1.8, 19.1) 17.7 (10.3, 25.1)
Week 24—delivery     
 TDF N 97 72 75
  Mean (95% CI) − 8.4 (− 14.8, − 2.0) − 30.7 (− 37.2, − 24.1) − 32.2 (− 42.3, − 22.2)
  Mean difference (95% CI) from TDF-ART   22.3 (12.1, 32.5) 23.9 (12.0, 35.7)
 No TDF N 74 86 82
  Mean (95% CI) − 5.2 (− 13.4, 3.0) − 16.6 (− 24.6, − 8.6) − 19.5 (− 29.6, − 9.5)
  Mean difference (95% CI) from TDF-ART   11.4 (1.0, 21.8) 14.3 (2.0, 26.6)
Week 6—delivery     
 TDF N 188 207 190
  Mean (95% CI) − 23.7 (− 29.6, − 17.8) − 38.6 (− 43.1, − 34.1) − 38.6 (− 42.6, − 34.5)
  Mean difference (95% CI) from TDF-ART   14.9 (7.0, 22.8) 14.8 (6.7, 23.0)
 No TDF N 199 189 212
  Mean (95% CI) − 12.5 (− 20.1, − 5.0) − 27.0 (− 31.0, − 23.0) − 31.7 (− 36.4, − 27.0)
  Mean difference (95% CI) from TDF-ART   14.5 (6.5, 22.5) 19.2 (11.3, 27.0)
Week 26—delivery     
 TDF N 192 206 195
  Mean (95% CI) − 17.9 (− 24.8, − 11.1) − 28.4 (− 34.5, − 22.4) − 29.3 (− 33.3, − 25.3)
  Mean difference (95% CI) from TDF-ART   10.5 (2.1, 18.9) 11.4 (4.0, 18.7)
 No TDF N 193 184 188
  Mean (95% CI) − 8.6 (− 12.8, − 4.3) − 19.0 (− 25.7, − 12.3) − 26.2 (− 31.6, − 20.9)
  Mean difference (95% CI) from TDF-ART   10.4 (1.8, 19.1) 17.7 (10.3, 25.1)
Week 74—delivery     
 TDF N 97 72 75
  Mean (95% CI) − 8.4 (− 14.8, − 2.0) − 30.7 (− 37.2, − 24.1) − 32.2 (− 42.3, − 22.2)
  Mean difference (95% CI) from TDF-ART   22.3 (12.1, 32.5) 23.9 (12.0, 35.7)
 No TDF N 74 86 82
  Mean (95% CI) − 5.2 (− 13.4, 3.0) − 16.6 (− 24.6, − 8.6) − 19.5 (− 29.6, − 9.5)
  Mean difference (95% CI) from TDF-ART   11.4 (1.0, 21.8) 14.3 (2.0, 26.6)
  1. *Among women eligible for TDF randomization
  2. CrCl creatinine clearance, TDF tenofovir disoproxil fumarate, ZDV zidovudine, CI confidence interval